Article Sidebar

PDF
Date Published: 25/11/2024
Abstract Views: 32
Views PDF: 18
DOI: https://doi.org/10.59873/vjid.v4i48.417
Issue
Vol. 4 No. 48 (2024)
Section
Scientific research
How to Cite
Ngo, V. L., Hoang, M. C., Nguyen, T. H., Dao, T. N., Le, V. T., Le, T. T. N., Phan, N. H. M., & Duong, H. Q. (2024). PERSONALIZED MEDICINE FOR DIAGNOSIS AND TREATMENT OF NON-SMALL-CELL LUNG CANCER. Vietnam Journal of Infectious Diseases, 4(48). https://doi.org/10.59873/vjid.v4i48.417

PERSONALIZED MEDICINE FOR DIAGNOSIS AND TREATMENT OF NON-SMALL-CELL LUNG CANCER

Van Lang Ngo1,, Minh Cong Hoang2, Thi Hue Nguyen3, Thi Nguyet Dao4, Van Thu Le5, Thi Thanh Nhan Le5, Nguyen Hoang Mai Phan5, Hong Quan Duong5
1 Phenikaa University
2 Yenphong Medical Center
3 Bac Giang General Hospital
4 Duc Giang General Hospital
5 Hanoi University of Public Health

Main Article Content

Abstract

Lung cancer, the most common cause of cancer death worldwide, with most patients dying from distant metastases, has become increasingly complex in achieving effective treatment. In lung cancer, particularly in non-small-cell lung cancer (NSCLC), EGFR, ALK, RET, ROS1, BRAF, KRAS, NRAS, NTRK, PIK3CA,
DDR2, MET, and ERBB2 have been reported as key oncogenic drivers, which have led to the development and application of targeted therapeutic drugs aimed at these dysfunctional genes. Personalized medicine based on these oncogenic drivers offers the greatest potential benefit in the diagnosis and treatment of NSCLC patients. In particular, personalized medicine is importantly recommended for the treatment of advanced NSCLC. Here, we briefly summarize the significant application of personalized medicine based on key oncogenic drivers for the diagnosis and treatment of NSCLC with targeted therapeutic drugs, both globally and Vietnam.

Article Details

Keywords

Personalized medicine, targeted therapy, lung cancer, non-small-cell lung cancer (NSCLC), diagnosis, treatment

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global caner statistics 2020: GLOBOCAN estimates of incidence
and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71: 209-249, 2021.
2. Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-smallcell lung cancer: Implications for current and future therapies. J Clin Oncol 31(8): 1039-1049, 2013.
3. https://www.medznat.ru/en/practice/medicalbilling/precision-and-personalized-medicineunlocking-the.
4. Reungwetwattana T, Dy GK. Targeted therapies in development for non-small cell lung cancer. J Carcinog 12: 22, 2013.
5. Xue Y, Hou S, Ji H, and Han X: Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance. Protein Cell 8(3): 178-190, 2017.
6. Du X, Shao Y, Qin HF, Tai YH and Gao HJ. ALK-rearrangment in non-small-cell lung cancer (NSCLC). Thorar Cancer. 9(4): 423-430, 2018.
7. Gainor JF and Shaw AT. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist. 18(7): 865-975, 2013.